Stock Events

Stock Events

Lytix Biopharma AS 

€0.89
3
-€0.03-3.28% Today

Statistics

Day High
0.89
Day Low
0.89
52W High
0.97
52W Low
0.41
Volume
0
Avg. Volume
-
Mkt Cap
60.48M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Jun 17
€0.85
Jul 16
€0.79
Jun 15
€0.6
Jun 14
€0.67
Jun 13
€0.64
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

17FebExpected
Q4 2021
-0.42
-0.09
0.24
0.58
Expected EPS
N/A
Actual EPS
-0.4232

Financials

-764.55%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
2.81MRevenue
-21.48MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6BG.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap294.39B
Merck & Co., Inc. develops oncology drugs that directly compete with Lytix's cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap122.85B
Bristol-Myers Squibb Company offers a range of immunotherapies in oncology, overlapping with Lytix's product pipeline.
Roche
RHHBY
Mkt Cap330.22B
Roche Holding AG is a leader in oncology, with a broad portfolio that competes in the same therapeutic areas as Lytix.
Pfizer
PFE
Mkt Cap156.77B
Pfizer Inc. has extensive investments in cancer treatment development, competing in the same market as Lytix Biopharma.
Novartis
NVS
Mkt Cap293.34B
Novartis AG focuses on innovative medicines in oncology, directly competing with Lytix's cancer therapies.
Astrazeneca
AZN
Mkt Cap317.5B
AstraZeneca PLC has a strong focus on oncology, particularly in developing new cancer treatments that compete with Lytix.
AMGEN
AMGN
Mkt Cap191.53B
Amgen Inc. develops therapies for various cancer types, competing with Lytix's research and development in oncology.
Gilead Sciences
GILD
Mkt Cap170.84B
Gilead Sciences, Inc. is involved in the development of oncology drugs, which places them in direct competition with Lytix.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.35B
Regeneron Pharmaceuticals, Inc. works on innovative cancer treatments, competing in the same niche as Lytix.
Johnson & Johnson
JNJ
Mkt Cap564.35B
Johnson & Johnson, through its pharmaceutical division, develops cancer therapies that compete with Lytix's products.

About

Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of LTX-315 for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma AS was founded in 2003 and is based in Oslo, Norway.
Show more...
CEO
Dr. Oystein Rekdal Ph.D.
Employees
14
Country
Other
ISIN
NO0010405780
WKN
000A3CSAK

Listings

STU
DE
6BG.STU
OL
NO
LYTIX.OL
F
DE
6BG.F

0 Comments

Share your thoughts

FAQ

What is Lytix Biopharma AS stock price today?▼
The current price of 6BG.F is €0.89 EUR — it has decreased by -3.28% in the past 24 hours. Watch Lytix Biopharma AS stock price performance more closely on the chart.
What is Lytix Biopharma AS stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lytix Biopharma AS stocks are traded under the ticker 6BG.F.
Is Lytix Biopharma AS stock price growing?▼
6BG.F stock has fallen by -3.28% compared to the previous week, the month change is a -7.13% fall, over the last year Lytix Biopharma AS has showed a +115.57% increase.
What is Lytix Biopharma AS market cap?▼
Today Lytix Biopharma AS has the market capitalization of 60.48M
What is Lytix Biopharma AS revenue for the last year?▼
Lytix Biopharma AS revenue for the last year amounts to 2.81M EUR.
What is Lytix Biopharma AS net income for the last year?▼
6BG.F net income for the last year is -21.48M EUR.
Does Lytix Biopharma AS pay dividends?▼
Yes, 6BG.F dividends are paid annual. The last dividend per share was 0.85 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Lytix Biopharma AS have?▼
As of April 22, 2026, the company has 14 employees.
In which sector is Lytix Biopharma AS located?▼
Lytix Biopharma AS operates in the Other sector.
When did Lytix Biopharma AS complete a stock split?▼
Lytix Biopharma AS has not had any recent stock splits.
Where is Lytix Biopharma AS headquartered?▼
Lytix Biopharma AS is headquartered in Oslo, Other.